Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × gemcitabine-oxaliplatin regimen × 1 year × Clear all
NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated
56 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡